金城医药(300233) - 2023 Q1 - 季度财报

Financial Performance - Net profit for the current period was 54,879,668.97, down from 116,066,574.08, representing a decline of approximately 52.73%[2] - Total comprehensive income attributable to the parent company decreased from 112,478,901.17 to 55,665,887.71, a decline of about 50.5%[2] - Net profit attributable to shareholders for Q1 2023 was ¥50,154,655, down 55.41% from ¥112,478,901 in the previous year[22] - The net profit attributable to the parent company decreased by 55.41% to ¥50,154,655.33 compared to ¥112,478,901.17 in the previous period, primarily due to a decline in the newly added intermediate CMO business[29] Earnings and Shares - Basic earnings per share decreased from 0.29 to 0.13, a drop of about 55.17%[2] - The basic earnings per share for Q1 2023 was ¥0.13, down 55.17% from ¥0.29 in the same period last year[22] Cash Flow - Cash inflow from operating activities increased from 661,072,899.99 to 772,155,286.99, an increase of approximately 16.79%[3] - The total cash flow from operating activities included 10,001,603.09 received from tax refunds, up from 7,508,060.50 in the previous period[3] - Net cash flow from operating activities improved to ¥26,703,337, compared to a negative cash flow of ¥45,797,444 in Q1 2022, representing a 158.31% increase[22] - The net cash flow from operating activities increased by 158.31% to ¥26,703,337.29, compared to a negative cash flow of ¥45,797,444.13 in the previous period, mainly due to an increase in sales collections[30] Assets and Liabilities - Total liabilities decreased slightly from 2,166,771,533.90 to 2,159,237,199.88, a reduction of approximately 0.57%[1] - Total assets at the end of Q1 2023 were ¥5,887,219,350.40, reflecting a 1.05% increase from ¥5,826,083,590.97 at the end of the previous year[22] - The company's equity attributable to shareholders increased by 1.77% to ¥3,671,272,645.90 from ¥3,607,438,065.73[22] - The total assets of the company reached CNY 5,887,219,350.40, up from CNY 5,826,083,590.97, reflecting a growth of about 1.06%[36] - The company's total liabilities were reported at CNY 2,790,796.70 for current liabilities, a decrease from CNY 3,760,327.97, indicating a reduction of about 25.73%[36] Expenses - Research and development expenses decreased from 43,235,054.66 to 28,502,407.61, a reduction of about 34.06%[8] - Sales expenses increased from 130,277,440.43 to 150,312,138.72, an increase of approximately 15.4%[8] - The total financial expenses rose by 88.64% to ¥7,965,178.08, attributed to an increase in exchange losses during the reporting period[29] Investments - The company's long-term equity investments increased by 32.12% to ¥19,556,722.62, resulting from increased external investments by subsidiaries during the reporting period[29] - The company's long-term equity investments rose to CNY 19,556,722.62 from CNY 14,802,516.67, an increase of approximately 32.5%[36] Cash and Equivalents - Cash and cash equivalents at the end of Q1 2023 totaled ¥825,415,392.71, up from ¥805,876,092.95 at the end of the previous year[22] - The company experienced a net increase in cash and cash equivalents of ¥35,635,968.30, contrasting with a decrease of -¥77,971,249.67 in Q1 2022[22] - Cash and cash equivalents reached CNY 926,336,241.84, up from CNY 859,028,154.40, indicating an increase of about 7.83%[34] Current Assets - The total current assets at the end of the period amounted to CNY 2,341,669,250.86, an increase from CNY 2,308,149,145.99 at the beginning of the year, reflecting a growth of approximately 1.45%[34] - Accounts receivable decreased slightly to CNY 575,924,203.06 from CNY 580,559,523.88, a decline of approximately 0.11%[34] - Inventory levels were reported at CNY 576,607,625.20, down from CNY 579,217,125.83, representing a decrease of about 0.45%[36] Other Financial Metrics - The company's tax payable decreased by 37.86% to ¥34,459,814.77, mainly due to a reduction in payable VAT and corporate income tax[29] - The company's special reserves increased significantly by 293.15% to ¥3,743,883.46, attributed to an increase in special reserve provisions during the reporting period[29]